EFTR — Effector Therapeutics Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$6.47m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2093.73% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 42 | 1.43 | 3.55 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +9713.48 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Directors
- Steve Worland PRE
- Michael Byrnes CFO
- Mark Densel VOP
- Alana McNulty OTH (47)
- Premal Patel OTH
- Brian Gallagher DRC
- Simeon George DRC
- Stefan Larson DRC
- David Maki DRC
- Denis Patrick DRC
- Jonathan Root DRC (61)
- John Smither DRC (67)
- Barbara Klencke IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 2nd, 2020
- Public Since
- January 8th, 2021
- No. of Shareholders
- 53
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,704,409
- Address
- 142 North Cedros Avenue, SOLANA BEACH, 92075
- Web
- https://effector.com/
- Phone
- +1 8589258215
- Contact
- Chris Calabrese
- Auditors
- Ernst & Young LLP
Upcoming Events for EFTR
Q1 2025 eFFECTOR Therapeutics Inc Earnings Release
Similar to EFTR
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Effector Therapeutics share price?
As of Today at 19:24 UTC, shares in Effector Therapeutics are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Effector Therapeutics share price performed this year?
Shares in Effector Therapeutics last closed at $0.00 and the price had moved by -99.96% over the past 365 days. In terms of relative price strength the Effector Therapeutics share price has underperformed the S&P500 Index by -99.97% over the past year.
What are the analyst and broker recommendations for Effector Therapeutics?
The overall consensus recommendation for Effector Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Effector Therapeutics dividend yield?
Effector Therapeutics does not currently pay a dividend.
Does Effector Therapeutics pay a dividend?
Effector Therapeutics does not currently pay a dividend.
When does Effector Therapeutics next pay dividends?
Effector Therapeutics does not currently pay a dividend.
How do I buy Effector Therapeutics shares?
To buy shares in Effector Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Effector Therapeutics?
As of the previous close price of $0.00, shares in Effector Therapeutics had a market capitalisation of $0.00m.
Where are Effector Therapeutics shares listed?
Here are the trading details for Effector Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EFTR
What kind of share is Effector Therapeutics?
Based on an overall assessment of its quality, value and momentum Effector Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Effector Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Effector Therapeutics is $10.00. That is 4999900% above the last closing price of $0.00.
Analysts covering Effector Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$6.17 for the next financial year.
Find out moreWhat is the trend in the Effector Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Effector Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -99.99%.
As of the last closing price of $0.00, shares in Effector Therapeutics were trading -99.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Effector Therapeutics PE Ratio?
The Effector Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Effector Therapeutics?
Effector Therapeutics' management team is headed by:
- Steve Worland - PRE
- Michael Byrnes - CFO
- Mark Densel - VOP
- Alana McNulty - OTH
- Premal Patel - OTH
- Brian Gallagher - DRC
- Simeon George - DRC
- Stefan Larson - DRC
- David Maki - DRC
- Denis Patrick - DRC
- Jonathan Root - DRC
- John Smither - DRC
- Barbara Klencke - IND